Aspen Technology (AZPN)
(Delayed Data from NSDQ)
$245.00 USD
-0.97 (-0.39%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $246.26 +1.26 (0.51%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$245.00 USD
-0.97 (-0.39%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $246.26 +1.26 (0.51%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth A Momentum D VGM
Zacks News
Aspen Q1 Earnings & Revenues Miss Estimates, Decline Y/Y
by Zacks Equity Research
Robust demand for the DGM suite cushions AZPN's first-quarter performance amid macroeconomic uncertainty.
Here's What Key Metrics Tell Us About Aspen Technology (AZPN) Q1 Earnings
by Zacks Equity Research
The headline numbers for Aspen Technology (AZPN) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Aspen Technology (AZPN) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Aspen Technology (AZPN) delivered earnings and revenue surprises of -43.71% and 20.24%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's What to Expect Ahead of Aspen's Q1 Earnings Release
by Zacks Equity Research
AZPN's first quarter of fiscal 2025 performance is likely to have benefited from demand momentum across energy and utility markets.
Paylocity (PCTY) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Paylocity (PCTY) delivered earnings and revenue surprises of 19.42% and 1.81%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Is Synchronoss Stock a Buy, Sell, or Hold at 0.73X Price-Sales Ratio?
by Aniruddha Ganguly
SNCR is an attractive stock for growth-oriented investors, given its portfolio strength and strong partner base. However, stretched valuation is a concern.
Aspen Unveils AspenTech MMS to Help Clients Achieve Net-Zero Targets
by Zacks Equity Research
AZPN's new Microgrid Management System solution is tailored to aid users in asset-intensive industries to boost power efficiency and meet net-zero targets.
3 Mid Cap Tech Stocks Primed to Outperform (HOOD, AZPN, VRT)
by Ethan Feller
Robinhood Markets, Aspen Technology and Vertiv all boast top Zacks Ranks and strong growth forecasts
Can Sapiens' Expansion Into Insurance Market Push the Stock Higher?
by Zacks Equity Research
SPNS empowers HGR with DataSuite, streamlining migration and enhancing data management for seamless operations.
The New York Times Company's Subscription Revenues Fuel Growth
by Zacks Equity Research
The New York Times Company has navigated the competitive media landscape by leaning into digital transformation and growing its subscription base.
Reasons to Retain Fresenius Medical Stock in Your Portfolio Now
by Zacks Equity Research
FMS continues to gain traction on the back of its broad dialysis product and service portfolio. Ongoing macro challenges raise concerns.
TD SYNNEX Beats on Q3 Earnings: Can Strong Sales View Lift the Stock?
by Zacks Equity Research
SNX's fiscal third-quarter performance reflects benefits from growth in the company's Advanced Solutions and Endpoint Solutions portfolios.
Can Synchronoss' Latest Personal Cloud Release Push the Stock Higher?
by Zacks Equity Research
SNCR's cloud subscriber base is expected to benefit from the launch of an enhanced version of the personal cloud.
Reasons to Retain Stryker Stock in Your Portfolio for Now
by Zacks Equity Research
SYK continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.
Micron Tops Q4 Earnings Estimates: Can Strong Guidance Lift the Stock?
by Zacks Equity Research
MU's Q4 performance reflects the benefits of the robust demand for the product portfolio across DRAM and NAND technologies.
Progress Software Beats Q3 Estimates: Guidance Raise to Lift Shares?
by Zacks Equity Research
PRGS' third-quarter fiscal 2024 results benefit from robust demand for multiple products in its portfolio.
Synchronoss Rises 111% YTD: Should Investors Buy SNCR Stock?
by Aniruddha Ganguly
SNCR is an attractive stock for growth-oriented investors, given its portfolio strength, and strong partner base.
AEIS Expands Into MedTech Field: How Should You Play the Stock?
by Zacks Equity Research
AEIS launches the NCF150 series of high-isolation AC-DC power supplies designed to meet stringent CF requirements for safe medical equipment operation.
MCHP's New VCSO's Expands Portfolio: How Should You Play the Stock?
by Zacks Equity Research
Microchip benefits from the latest launch of the 101765-320-A VCSO. Persistent inflation and high interest rates are a major concern.
Will Microchip's Graphics Suite Launch Push the Stock Higher?
by Zacks Equity Research
Microchip Technology introduces the Graphics Suite, simplifying GUI integration for developers and enhancing user experiences across diverse devices.
VTEX Stock Declines 7% in a Month: Should Investors Buy the Dip?
by Aniruddha Ganguly
VTEX is an attractive stock for growth-oriented investors, given its expanding clientele and global footprint.
TER Partners With Siemens for Robotics: How Should You Play the Stock?
by Zacks Equity Research
Teradyne and Siemens team up to introduce advanced robotics showcase at MxD in Chicago, featuring advanced cobots, MiRs and real-world applications.
DDD Boosts Dental 3D Printing: How Should Investors Play the Stock?
by Zacks Equity Research
3D Systems gains FDA clearance for its advanced jetted denture solution, enhancing durability and efficiency in dental labs for an improved patient experience.
Fastly Rises 11% in a Month: Should Investors Buy the FSLY Stock?
by Zacks Equity Research
FSLY shares are buoyed by top-line revenue growth expectations, edge cloud innovation and solid go-to-market transformation.
Amphenol Rises 28% Year to Date: How Should You Play the Stock?
by Zacks Equity Research
APH excels with growing end-market demand and smart acquisitions, backed by solid cash flow to sustain its current dividend payouts.